Latest News and Press Releases

Media Release Promising efficacy and tolerability reported from efti plus anti-PD-1 therapy and doublet chemotherapy as first line therapy in metastatic non-squamous non-small cell lung cancer...

Perth, Oct. 24, 2023 (GLOBE NEWSWIRE) -- SEPTEMBER 2023 QUARTER REPORT Perseus continues its market leading operating performance, increasing its cash and bullion balance to US$594M. PERTH,...

Media Release Median Overall Survival reaches 35.5 months in first-line treatment of metastatic non-small cell lung cancer patients expressing PD-L1 (TPS >1%), 23.4 months in patients with low...

VALENCIA, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class...

DENVER, Oct. 19, 2023 (GLOBE NEWSWIRE) -- American Rare Earths (ASX: ARR | ADRs - OTCQX: AMRRY | Common Shares - OTCQB: ARRNF| FSE:1BHA) (ARR or the Company) announces results from its metallurgical...

Shoham, Israel, Oct. 19, 2023 (GLOBE NEWSWIRE) --  Mobilicom Limited (Mobilicom or the Company, NASDAQ: MOB, MOBBW), a provider of cybersecurity and robust solutions for drones and robotics, today...

Semiconductor foundry DB HiTek licensed Weebit ReRAM for customers to integrate as embedded NVM into SoCs for analog, mixed-signal and power designs.

AVITA Medical announces third quarter 2023 preliminary commercial revenue of $13.5 million and secures up to $90 million of non-dilutive debt financing.

MELBOURNE, Australia, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and...

Highlights: Second cohort of 34 healthy volunteers enrolled in the Travelan® Clinical Trial Clinical Trial to examine a dosing regimen for Travelan® more suited to the US military has commenced...